Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elnaz Ostad Haji"'
Publikováno v:
Therapeutic Drug Monitoring. 35:279-282
We describe a female patient who was an extensive metabolizer of cytochrome P450 isoenzyme (CYP) 2D6 and an intermediate metabolizer of CYP2C19 (genotype: CYP2C19 *1/*2). She exhibited high serum concentrations of venlafaxine and O-desmethylvenlafaxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97157f79916c03d7b7ba7b45b7714c5b
https://doi.org/10.1097/ftd.0b013e31828816e0
https://doi.org/10.1097/ftd.0b013e31828816e0
Autor:
M. L. Rao, Miriam Fric, André Tadić, A. Dragicevic, Christoph Hiemke, K Boland, Matthias J. Müller, Gerd Laux, Elnaz Ostad Haji, Stefanie Wagner
Publikováno v:
Journal of Clinical Psychopharmacology. 31:281-286
Imaging studies have shown that serum concentrations of the selective serotonin reuptake inhibitor citalopram correlate with serotonin transporter (5-HTT) occupancy in vivo. In patients with major depressive disorders treated with citalopram, 80% 5-H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c8b5eae0908cb5aab3f775651c1e01e
https://doi.org/10.1097/jcp.0b013e318218f503
https://doi.org/10.1097/jcp.0b013e318218f503
Autor:
Stefanie Wagner, Elnaz Ostad Haji, M. Fric, Gerd Laux, Patrick Pittermann, Christoph Hiemke, Joachim Röschke
Publikováno v:
Therapeutic drug monitoring. 35(4)
Quetiapine has been recently approved as an add-on therapy in the treatment of major depressive disorders in the case of inadequate response to antidepressant monotherapy. Thereby the antidepressant potential is attributed to the N-demethylated metab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23eb7eab931c152d86d4e69f6f86c3a5
https://pubmed.ncbi.nlm.nih.gov/23739636
https://pubmed.ncbi.nlm.nih.gov/23739636
Publikováno v:
Current pharmaceutical design. 18(36)
The aim of antidepressant drug treatment is to produce remission without causing adverse effects during the acute phase of the illness and to prevent relapses or recurrences during continuation or maintenance therapy. To achieve these goals, drug cho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a03e4c02bb832ed6c6d3c46f91a8543
https://pubmed.ncbi.nlm.nih.gov/22681162
https://pubmed.ncbi.nlm.nih.gov/22681162
Autor:
Elnaz Ostad Haji
Publikováno v:
InFo Neurologie & Psychiatrie. 14:16-16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fae35de1a3b03ce5c149a670fca703ba
https://doi.org/10.1007/s15005-012-0162-3
https://doi.org/10.1007/s15005-012-0162-3